Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.

Marangoni K, Neves AF, Cardoso AM, Santos WK, Faria PC, Goulart LR.

Cancer Detect Prev. 2006;30(1):7-13. Epub 2006 Feb 2.

PMID:
16458450
2.

The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression.

Marangoni K, Araújo TG, Neves AF, Goulart LR.

BMC Cancer. 2008 Sep 29;8:273. doi: 10.1186/1471-2407-8-273.

3.

Gene expression profile in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.

Alonso V, Neves AF, Marangoni K, Faria PC, Freschi AP, Capaneli AC, Meola J, Goulart LR.

Cancer Detect Prev. 2009;32(4):336-7. doi: 10.1016/j.cdp.2008.10.001. Epub 2008 Nov 20.

PMID:
19026495
4.

Endothelial nitric oxide synthase gene polymorphisms and the shedding of circulating tumour cells in the blood of prostate cancer patients.

Medeiros R, Morais A, Vasconcelos A, Costa S, Carrilho S, Oliveira J, Lopes C.

Cancer Lett. 2003 Jan 10;189(1):85-90.

PMID:
12445681
5.

Transforming growth factor-beta 1 gene polymorphisms and expression in the blood of prostate cancer patients.

Faria PC, Saba K, Neves AF, Cordeiro ER, Marangoni K, Freitas DG, Goulart LR.

Cancer Invest. 2007 Dec;25(8):726-32.

PMID:
18058470
6.

Differential display code 3 (DD3/PCA3) in prostate cancer diagnosis.

Klecka J, Holubec L, Pesta M, Topolcan O, Hora M, Eret V, Finek J, Chottova-Dvorakova M, Babjuk M, Novak K, Stolz J.

Anticancer Res. 2010 Feb;30(2):665-70.

PMID:
20332487
7.

Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu-Asp298 polymorphism at exon 7.

Medeiros RM, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Ferreira P, Lopes C.

Clin Cancer Res. 2002 Nov;8(11):3433-7.

8.

Endothelial nitric oxide synthase gene polymorphisms and genetic susceptibility to prostate cancer.

Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C.

Eur J Cancer Prev. 2002 Aug;11(4):343-50.

PMID:
12195160
9.

[Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].

Weng ZL, Yu KY, Mao XL, Tao ZH, Chen XD, Wu XL, Hu YP, Wang SQ, Li CD, Chen ZG.

Zhonghua Yi Xue Za Zhi. 2006 Nov 7;86(41):2911-5. Chinese.

PMID:
17288789
10.

Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer.

Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, Kinoshita H, Kamoto T, Nakamura A, Ogawa O, Kato T.

Cancer Res. 2003 Aug 1;63(15):4407-11.

11.

DD3(PCA3) gene expression in cancer and prostatic hyperplasia.

Floriano-Sánchez E, Cárdenas-Rodríguez N, Castro-Marín M, Alvarez-Grave P, Lara-Padilla E.

Clin Invest Med. 2009 Dec 1;32(6):E258.

PMID:
20003831
13.

The influence of G-protein beta3-subunit gene and endothelial nitric oxide synthase gene in exon 7 polymorphisms on progression of autosomal dominant polycystic kidney disease.

Reiterová J, Miroslav M, Stekrová J, Kohoutová M, Tesar V, Kmentová D, Hubácek JA, Viklický O.

Ren Fail. 2004 Mar;26(2):119-25.

PMID:
15287194
14.

[Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction].

Tao ZH, Mao XL, Wang CH, Chen XD, Yu KY, Weng ZL, Hu YP, Zhang XH, Xie H, Wang OC, Song QT, Li CD, Chen ZG.

Zhonghua Nan Ke Xue. 2007 Feb;13(2):130-3. Chinese.

PMID:
17345768
15.

Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2.

Kawakami M, Okaneya T, Furihata K, Nishizawa O, Katsuyama T.

Cancer Res. 1997 Oct 1;57(19):4167-70.

16.

Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue.

Bialkowska-Hobrzanska H, Driman DK, Fletcher R, Harry V, Razvi H.

Can J Urol. 2006 Feb;13(1):2967-74.

PMID:
16515751
17.

Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.

Zhang L, Wang CY, Yang R, Shi J, Fu R, Chen L, Klocker H, Zhang J.

Urol Oncol. 2008 Nov-Dec;26(6):634-40. doi: 10.1016/j.urolonc.2007.07.016. Epub 2008 Jan 14.

PMID:
18367130
18.

Despite the lack of association between different genotypes and the presence of prostate cancer, endothelial nitric oxide synthase a/b (eNOS4a/b) polymorphism may be associated with advanced clinical stage and bone metastasis.

Sanli O, Kucukgergin C, Gokpinar M, Tefik T, Nane I, Seckin S.

Urol Oncol. 2011 Mar-Apr;29(2):183-8. doi: 10.1016/j.urolonc.2009.04.011. Epub 2009 Jul 3. Erratum in: Urol Oncol. 2011 Jul-Aug;29(4):467.

PMID:
19576798
19.

Lack of association between Glu(298) asp polymorphism of endothelial nitric oxide synthase (eNOS) gene and coronary artery disease in Tamilian population.

Mathew J, Narayanan P, Sundaram R, Jayaraman B, Dutta TK, Raman SK, Chandrasekaran A.

Indian Heart J. 2008 May-Jun;60(3):223-7.

PMID:
19240311
20.

The Glu298Asp polymorphism of the NOS 3 gene as a determinant of the baseline production of nitric oxide.

Veldman BA, Spiering W, Doevendans PA, Vervoort G, Kroon AA, de Leeuw PW, Smits P.

J Hypertens. 2002 Oct;20(10):2023-7.

PMID:
12359981
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk